Future Diagnostics Enters Agreement with DIAsource Immunoassays for Free 25OH Vitamin D ELISA product

DIAsource Immunoassays is a diagnostic company specialized in the development, manufacturing, sales and distribution of immunoassay tests and open instrumentation solutions for clinical diagnostics. It delivers manual RIA and ELISA kits as well as open automation solutions to the international markets, and has a portfolio of over 190 ELISA and 140 RIA assays. Future Diagnostics provides in vitro diagnostic (IVD) assay development services – for start-ups, mid-sized biotech companies and multinationals in the global IVD medical device market. The 75+ experts develop many different types of immunoassays with different technologies, either manually or on automated platforms. They operate under an ISO13485 certified quality management system and have their own FDA registered manufacturing facility, offering small to medium scale production capabilities.

Both the companies have long standing collaborations for more than 10 years, with DIAsource already successfully commercializing the Free 25OH Vitamin D ELISA product, exclusively worldwide. The current transfer of this product to DIAsource is in line with its strategy to remain a leader in the diagnostic of Vitamin D deficiency. This product complements the Vitamin D portfolio of DIAsource that includes >10 products for the measurement of both 25OH and 1,25(OH)2 Vitamin D. Effective June 8th, 2020, DIAsource Immunoassays has assumed manufacturing and commercial ownership of the Free 25OH Vitamin D ELISA and will service clients from order to shipment, while Future Diagnostics will remain the owner of the product related IP and grants DIAsource an exclusive licence, enabling all necessary activities. The transfer of production will be done in close collaboration and will be completed by July 4th, 2020.

The measurement of the free fraction of 25OH Vitamin D represents a more accurate method to diagnose Vitamin D deficiency than the currently used Vitamin D assays, especially in conditions where the Vitamin D Binding Protein concentrations are altered. This includes, amongst others, pregnancy, kidney and liver diseases, critical illness and obesity.

“Developing and manufacturing high-quality IVD assays is Future Diagnostic’s core business. To leverage market opportunity and allow our Free 25OH Vitamin D ELISA to reach its full potential, we were looking for a party who has the expertise and resources to take on our Free Vitamin D activities and take it to the next level, ” said Mike Martens, Scientific Business Executive of Future Diagnostics. “By entering into this strategic agreement with DIAsource, an experienced and reliable partner for years to Future Diagnostics, we believe that the assays will receive the attention it deserves and needs.”

“This acquisition is yet another step in our strategy to position DIAsource as a consolidator of manual specialty assays, after previous acquisitions of the Intertech RIA product line in 2012, of the Viro-Immun ELISA product lines in 2017, and of Svar Life Science and ZenTech RIA product lines in 2018. DIAsource also acquired the RIA client businesses from distribution partners in France and Spain in 2015 and 2016. This new acquisition in the field of Vitamin D demonstrates our commitment to the long term future servicing and support of the diagnosis of Vitamin D deficiency,” said Béatrice de Borman, CEO of DIAsource Immunoassays. “We experience that the measurement of Vitamin D remains important all over the world and still raises questions at the same time. We strongly believe that measuring the free fraction of 25OH Vitamin D represents the next generation methodology and will complement or replace the actual measurement performed by clinical laboratories. DIAsource now has a unique position by combining the most complete offering of Vitamin D assays on the market with this unique and innovative product.” added Béatrice de Borman.